Not just Holistic, but how to use E: All of the Above!

I made this blog because I did tons of research on success stories and research worldwide and used it on my dog with nasal cancer named Lucy. So, now my hobby is molecular biology. The treatment uses combination of health store supplements, some prescription meds, diet changes, and specific Ayurvedic and Chinese medicinal herbs. I just wanted her to have a better quality of life. I thought this combination of E: All the Above (except no radiation or chemo and surgery for this cancer was not an option) would help that for sure, but it actually put her bleeding nasal cancer in remission!
My approach to cancer is about treating the whole animals biologic system. But I do hate the word 'Holistic'. Sounds like hoo hoo. This is science based, research based data and results of using active herbal compounds that happen to be readily available and common. Some call it Nutriceuticals. Others may call it Orthomolecular cancer therapy. Or Cancer Immunotherapy.
I FEEL DIVERSITY IN TREATMENT IS KEY:
-Slow cancer cell reproduction
-Make cancer cells become easier targets for the immune system
-Kill the cancer cells
-Rid the cancer cells
-Remove the toxins it produces
- Stimulate and Modulate the immune system
-Control secondary symptoms like bleeding, infection, inflammation, mucous, appetite, or pain for a better feeling animal
-Working with your vet for exams and prescriptions that are sometimes needed when conditions are acute.
Just by using a multi-modal treatment approach that is as diverse in attack as possible. Both conventional and natural.
The body conditions that allowed it to develop in the first place must be corrected. If caught early enough, like with Lucy, this ongoing maintenance correctional treatment is all that was required at this point to achieve, so far, more than 10 TIMES the life expectancy given (more than 60 months) after diagnosis WITH remission. I did not use radiation or chemotherapy or surgery.
I hope this cancer research can help your dog as well.

My Lucy

My Lucy
In Loving Memory my Lucy December 2016
CURRENT STATUS - It was for more than 5 YEARS after Lucy was diagnosed by biopsy in March 2011 with nasal cancer that she lived. And she was in remission for 4 of 5 years using no radiation or chemo! Now multiply that by 7 to be 35 years extended!! She was 12.5 years old - equivalent to almost 90 human years old. She ended her watch December 1, 2016. I miss her so much.

November 26, 2013

Study finds gut microorganisms may determine cancer treatment outcome

NIH mouse study finds gut microorganisms may determine cancer treatment outcome

 

An intact population of microorganisms that derive food and benefit from other organisms living in the intestine is required for optimal response to cancer therapy, according to a mouse study by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, and their collaborators.
 
NCI scientists found that tumors of germ-free mice (mice completely lacking these microorganisms), or mice treated with antibiotics to deplete the gut of bacteria, were largely impaired in their ability to respond to immunotherapy that slows cancer growth and prolongs survival. The mice were also impaired in their ability to respond to mainstay chemotherapy drugs such as oxaliplatin and cisplatin. These findings in mice may underscore the importance of microorganisms in optimal cancer treatment outcomes in humans. The study, led by Romina Goldszmid, Ph.D., staff scientist, NCI, and Giorgio Trinchieri, M.D., director of the Cancer and Inflammation Program, Center for Cancer Research, NCI, appeared Nov. 22, 2013, in Science.
 
Gut commensal microbiota are microorganisms that live in the gut and thrive but do not affect their host, in this case laboratory mice. Humans also harbor gut commensal microbiota that can influence local and body-wide inflammation as well as modify the tumor microenvironment, which consists of cells, signaling molecules and mechanisms that may support tumor growth and also cause drug resistance.
 
To study the importance of commensal bacteria, the scientists used mice raised in sterile conditions from birth so they did not harbor any bacteria, or alternatively, conventionally raised mice that received a potent antibiotic cocktail that is known to decrease bacteria by more than 10,000–fold. The mice received these antibiotics in their drinking water, starting three weeks prior to tumor inoculation. They continued to receive doses of the antibiotic cocktail throughout the experiment.
To analyze tumors at comparable stages of progression, lymphoma, colon, and melanoma cancers that could be transplanted were selected, based on their susceptibility to therapeutic drugs. Cancer cells from these tumors were then injected under the skin of the mice, where they formed tumors that grew to reach a diameter of one-fifth of an inch or more. The tumors were then treated with an immunotherapy that included CpG-oligonucleotides, which stimulated the immune system, or with the chemotherapy drugs oxaliplatin and cisplatin, which attacked the tumors.
 
Germ-free mice, or mice that received the antibiotic cocktail, responded poorly to drug therapy for their tumors. This resulted in a lower production of cytokines (proteins secreted by lymph cells that affects cellular activity and controls inflammation) as well as lower tumor death therefore demonstrating that optimal responses to cancer therapy required an intact commensal microbiota.
In an independent co-submitted study that will appear in the same issue of Science, Laurence Zitvogel, M.D., Ph.D., Gustave Roussy Institute, Paris, and colleagues showed that a different type of chemotherapy drug, cyclophosphamide, altered the composition of the intestinal microbiota and damaged the intestinal wall, thereby affecting optimal anti-tumor immune response and the therapeutic effectiveness of cyclophosphamide.
 
“The use of antibiotics should be considered as an important element affecting microbiota composition. It has been demonstrated, and our present study has confirmed, that after antibiotic treatment the bacterial composition in the gut never returns to its initial composition,” said Trinchieri. “Thus, our findings raise the possibility that the frequent use of antibiotics during a patient’s lifetime or to treat infections related to cancer and its side-effects may affect the success of anti-cancer therapy.”
 
In next steps, Goldszmid and Trinchieri will work in mice to fully characterize the molecular signaling by which the bacteria in the gut can actually send messages to distant organs or tumors and change the type and level of inflammation present in those organs. They also plan to characterize, in humans, the role of gut bacteria on the bodies’ inflammatory response and tumor response to therapy. Additionally, the researchers plan to design clinical studies by giving antibiotics to healthy volunteers to study their effect on the molecular mechanisms regulating inflammation.
 
The National Cancer Institute (NCI) leads the National Cancer Program and the NIH effort to dramatically reduce cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at http://www.cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
 
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.